Zenas BioPharma, Inc. (ZBIO)
Automate Your Wheel Strategy on ZBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBIO
- Rev/Share 0.3558
- Book/Share 4.6592
- PB 5.6104
- Debt/Equity 0.0041
- CurrentRatio 5.6588
- ROIC -0.7427
- MktCap 1095251388.0
- FreeCF/Share -3.7611
- PFCF -6.9073
- PE -5.8033
- Debt/Assets 0.0025
- DivYield 0
- ROE -0.7355
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZBIO | Morgan Stanley | Overweight | Equal Weight | -- | $19 | Jan. 5, 2026 |
| Initiation | ZBIO | Wedbush | -- | Outperform | -- | $35 | March 20, 2025 |
| Initiation | ZBIO | Wolfe Research | -- | Outperform | -- | $19 | Feb. 4, 2025 |
| Initiation | ZBIO | H.C. Wainwright | -- | Buy | -- | $30 | Dec. 16, 2024 |
| Initiation | ZBIO | Morgan Stanley | -- | Overweight | -- | $40 | Oct. 8, 2024 |
| Initiation | ZBIO | Guggenheim | -- | Buy | -- | $45 | Oct. 8, 2024 |
| Initiation | ZBIO | Jefferies | -- | Buy | -- | $35 | Oct. 8, 2024 |
| Initiation | ZBIO | Citigroup | -- | Buy | -- | $27 | Oct. 8, 2024 |
News
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options
Read More
Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc. (ZBIO)
Published: April 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=145129&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ZBIO
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=145098&wire=1 or contact Joseph E. Levi, Esq.
Read More
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
Published: April 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144946&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (NASDAQ: ZBIO); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
Published: April 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) (“Zenas” or the “Company”) securities pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas' initial public offering held on September 13, 2024 (the “IPO”), charging the Company, certain senior executives and directors, and the underwriters of the IPO with violations of the federal securities laws (collectively, “Defendants”).
Read More
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: April 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144925&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Published: April 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as …
Read More
Zenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
Published: April 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144751&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZBIO Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Zenas BioPharma, Inc. Class Action
Published: April 23, 2025 by: Accesswire
Sentiment: Neutral
SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ:ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering.Zenas BioPharma purports to be a "clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a …
Read More
ZBIO LAWSUIT ALERT: The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).
Read More
Shareholders that Lost Money on Zenas BioPharma, Inc. (ZBIO) Should Contact Levi & Korsinsky About Pending Class Action - ZBIO
Published: April 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144704&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NYSE: ZBIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Shareholders that lost money on Zenas BioPharma, Inc. (ZBIO) should contact Levi & Korsinsky about pending Class Action - ZBIO
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144485&wire=1 or contact Joseph E. Levi, Esq.
Read More
Zenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144461&wire=1 or contact Joseph E. Levi, Esq.
Read More
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who acquired shares in the company's September 2024 initial public offering (“IPO”). The firm urges affected investors to contact the firm promptly to discuss their legal rights and recovery options.
Read More
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ:ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").
Read More
Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc.(ZBIO)
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) should contact Levi & Korsinsky about pending Class Action - ZBIO
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144370&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZENAS BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. and Encourages Investors to Contact the Firm
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or the “Company”) (NASDAQ:ZBIO) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering (the “Class Period”). Investors have until June 16, 2025 to apply to the Court …
Read More
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144288&wire=1 or contact Joseph E. Levi, Esq.
Read More
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.
Read More
Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the Company's September 2024 initial public offering (“IPO”). Investors who suffered significant losses are encouraged to contact the firm.
Read More
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ("IPO") conducted on September 13, 2024, are encouraged to contact the firm before June 16, 2025.
Read More
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144188&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ:ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").
Read More
Investors Who Lost Money on Zenas BioPharma, Inc. (ZBIO) Should Contact Levi & Korsinsky about Pending Class Action - ZBIO
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144162&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , April 21, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v.
Read More
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
About Zenas BioPharma, Inc. (ZBIO)
- IPO Date 2024-09-13
- Website https://zenasbio.com
- Industry Biotechnology
- CEO Leon Oliver Moulder Jr.
- Employees 130